Company Overview
Marker Therapeutics, Inc. operates as a clinical-stage immuno-oncology entity focused on developing and commercializing T cell-based immunotherapies specifically for the treatment of hematological malignancies and solid tumor indications within the United States. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to leverage advancements in cellular therapy technologies. Currently, the organization maintains a very small operational scale, employing only five individuals while holding a market capitalization of $16.82M. This limited employee count combined with a market cap of $16.82M indicates that the company is in an early-stage development phase where capital efficiency is critical. Furthermore, the annual revenue of $3.55M reflects the current stage of commercialization and clinical progression, suggesting that the company is generating modest sales relative to its peers in larger, more mature biotechnology markets. The small size of the workforce and the modest revenue stream highlight the resource-intensive nature of the immuno-oncology space, where significant capital is often required to advance clinical trials before substantial commercial returns can be realized.
Financial Health
The company reported a revenue of $3.55M over the trailing twelve months, yet this figure stands in stark contrast to a net income of $-12,163,620, revealing a cost structure where expenses significantly outpace revenue generation. This substantial gap between revenue and net income indicates that the company is operating at a deep loss, a common characteristic for clinical-stage biotechnology firms investing heavily in research and development. Additionally, the EBITDA is listed as N/A, which precludes a direct assessment of operating cash earnings before interest, taxes, depreciation, and amortization using standard metrics. The free cash flow stands at $-8,598,567, signifying that the company is burning cash at a rapid rate, which necessitates a reliance on external financing or existing cash reserves to sustain operations. Margin analysis shows a gross margin of -232.7%, an operating margin of -170.7%, and a profit margin of 0.0%, all of which indicate severe operational inefficiencies or high upfront costs relative to sales, typical of companies in the clinical development phase. Despite the negative net income, the company holds $16.07M in cash against N/A in debt, providing a substantial liquidity buffer against its current obligations. The current ratio is reported at 8.39, which suggests a very strong short-term liquidity position capable of meeting immediate financial liabilities many times over. Finally, the return on equity is -68.8% and the return on assets is -37.8%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets due to the high burn rate and lack of profitability.
Valuation Assessment
Valuation metrics for Marker Therapeutics present a complex picture, with a trailing P/E ratio of N/A due to the company's lack of earnings, while the forward P/E is listed at -6.84, implying an expectation of future losses or a mathematical anomaly in forward projections for a pre-profit entity. The price-to-book ratio stands at 1.29, indicating that the market values the company at 129% of its book value, suggesting a slight premium over the net asset value despite the lack of current earnings. The price-to-sales ratio is 4.74, which is a high multiple for a company with negative earnings, reflecting investor willingness to pay for potential future clinical successes and intellectual property. The EV/EBITDA ratio is N/A, preventing a traditional enterprise value analysis based on operating leverage. Regarding trading range, the 52-week high is $4.07 and the 52-week low is $0.81, meaning the current price sits somewhere within this volatile band, though the exact percentage below the high requires the current price which is not explicitly provided in the text, only the range bounds. The beta value is 1.45, which indicates that the stock price is significantly more volatile than the broader market, moving 45% more than the average market stock in response to market fluctuations.
Growth & Income
The company experienced a revenue growth rate of -51.0% year-over-year, while earnings growth is N/A due to the absence of positive earnings, indicating that the business is currently contracting or adjusting its commercial footprint rather than expanding. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows the standard biotechnology model of reinvesting all available earnings and cash reserves into growth initiatives, clinical trials, and operational scaling rather than distributing income to shareholders. The absence of a dividend payout ratio further confirms that the company prioritizes capital deployment for research and development over returning value to investors in the form of cash dividends. Consequently, the overall growth and income profile is characterized by significant revenue contraction, negative earnings, and a complete lack of dividend income, relying entirely on the potential for future clinical milestones to drive value appreciation.